The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
The Effect of a Pure Antiandrogen Receptor Blocker, Flutamide, on the Lipid Profile in the Polycystic Ovary Syndrome
Abstract
Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies affecting women of reproductive age; it is associated with hyperandrogenism, hyperinsulinemia, and dyslipidemia. This study was designed to assess the long term effects of a pure androgen receptor blocker, flutamide, on the lipid profile in women with PCOS and to examine the possible mechanisms by which androgens may exert their influence. Seventeen women with PCOS (10 obese and 7 lean) were studied. All subjects received a 12-week course of oral flutamide (500 mg/day). The baseline and posttreatment evaluations included lipid profile, androgen levels, insulin sensitivity, and serum catecholamine determinations. The primary outcome was the change in the ratio of low density lipoproteins (LDL) to high density lipoproteins (HDL). Treatment with flutamide was associated with a significant decrease in the LDL/HDL ratio by 23% (P = 0.005), in total cholesterol by 18% (P < 0.0001), in LDL by 13% (P = 0.002), and in triglycerides by 23% (P = 0.002). Flutamide treatment was also associated with a trend toward an increase in HDL (by 14%; P = 0.14). The effects on lipid profile were found regardless of obesity and were not associated with a change in weight. Furthermore, actions of flutamide on lipid metabolism were not associated with significant changes in circulating adrenaline or noradrenaline, glucose metabolism, or insulin sensitivity. This report has demonstrated for the first time that treatment with the pure antiandrogen, flutamide, may improve the lipid profile and that this effect may be due to direct inhibition of androgenic actions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NESTLER, J. E., POWERS, L. P., MATT, D. W., STEINGOLD, K. A., PLYMATE, S. R., RITTMASTER, R. S., CLORE, J. N., & BLACKARD, W. G. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-1-83 · Cited by 815
Splanchnic insulin metabolism in obesity. Influence of body fat distribution.
Peiris, A. N., Mueller, R. A., Smith, G. A., Struve, M. F., & Kissebah, A. H. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112758 · Cited by 346
GRAF, M. J., RICHARDS, C. J., BROWN, V., MEISSNER, L., & DUNAIF, A. (1990) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1990.tb00472.x · Cited by 89
Cited by
Androgens and Coronary Artery Disease
Wu, F. C. W., & von Eckardstein, A. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0025 · Cited by 592
Obesity and reproductive disorders in women
Pasquali, R. (2003) · Human Reproduction Update · doi:10.1093/humupd/dmg024 · Cited by 539
Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics
Singh, S., Pal, N., Shubham, S., Sarma, D. K., Verma, V., Marotta, F., & Kumar, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041454 · Cited by 521
Obesity and androgens: facts and perspectives
Pasquali, R. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.10.054 · Cited by 469
Rinella, M. E., & Green, R. M. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2003.09.020 · Cited by 460
Coviello, A. D., Legro, R. S., & Dunaif, A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1666 · Cited by 447
Osibogun, O., Ogunmoroti, O., & Michos, E. D. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.08.010 · Cited by 423
Pathophysiology and types of dyslipidemia in PCOS
Diamanti-Kandarakis, E., Papavassiliou, A. G., Kandarakis, S. A., & Chrousos, G. P. (2007) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2007.07.004 · Cited by 299
Self-citationPolycystic ovarian syndrome: Pathophysiology, molecular aspects and clinical implications
Diamanti-Kandarakis, E. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000598 · Cited by 294
Self-citationThe pathophysiology of polycystic ovary syndrome
Tsilchorozidou, T., Overton, C., & Conway, G. S. (2004) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01842.x · Cited by 294
Emerging Role of Nrf2 in Protecting Against Hepatic and Gastrointestinal Disease
Aleksunes, L. M., & Manautou, J. E. (2007) · Toxicologic Pathology · doi:10.1080/01926230701311344 · Cited by 285
Gambineri, A., Pelusi, C., Genghini, S., Morselli‐Labate, A. M., Cacciari, M., Pagotto, U., & Pasquali, R. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.01973.x · Cited by 216
Obesity I: Overview and molecular and biochemical mechanisms
Lustig, R. H., Collier, D., Kassotis, C., Roepke, T. A., Kim, M. J., Blanc, E., Barouki, R., Bansal, A., Cave, M. C., Chatterjee, S., et al. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115012 · Cited by 203
The management of patients with polycystic ovary syndrome
Jayasena, C. N., & Franks, S. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.102 · Cited by 196
New Perspectives on the Pathogenesis of PCOS: Neuroendocrine Origins
Walters, K. A., Gilchrist, R. B., Ledger, W. L., Teede, H. J., Handelsman, D. J., & Campbell, R. E. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.08.005 · Cited by 186
Androgens and ovarian function: translation from basic discovery research to clinical impact
Walters, K. A., Rodriguez Paris, V, Aflatounian, A., & Handelsman, D. J. (2019) · Journal of Endocrinology · doi:10.1530/joe-19-0096 · Cited by 104
Fruzzetti, F., Perini, D., Lazzarini, V., Parrini, D., & Genazzani, A. R. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.06.004 · Cited by 95
Cardiometabolic Risk in PCOS: More than a Reproductive Disorder
Torchen, L. C. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0956-2 · Cited by 65
Puttabyatappa, M., Andriessen, V., Mesquitta, M., Zeng, L., Pennathur, S., & Padmanabhan, V. (2017) · Endocrinology · doi:10.1210/en.2017-00460 · Cited by 42
Vine, D., Wang, Y., Jetha, M., Ball, G., & Proctor, S. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2854 · Cited by 40
Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
Cignarella, A., Mioni, R., Sabbadin, C., Dassie, F., Parolin, M., Vettor, R., Barbot, M., & Scaroni, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249554 · Cited by 36
Zhu, X., Li, Y., Jiang, Y., Zhang, J., Duan, R., Liu, L., Liu, C., Xu, X., Yu, L., Wang, Q., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.665406 · Cited by 32
Zhang, D., Gao, J., Liu, X., Qin, H., & Wu, X. (2021) · Reproductive Sciences · doi:10.1007/s43032-020-00316-1 · Cited by 23
Neuronal androgen receptor: molecular gateway to polycystic ovary syndrome
Abbott, D. H. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1703436114 · Cited by 20
Metadata
- Authors
- Diamanti-Kandarakis, E., Mitrakou, A., Raptis, S., Tolis, G., & Duleba, A. J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1998-08-01
- Volume
- 83
- Issue
- 8
- Pages
- 2699-2705
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1979933675
- Cited by
- 158
- References
- 3
- FWCI
- 4.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.